Elevated TG levels was able to increase IL-6 concentrations in cerebrospinal fluid (16) and augment the risk of subsequent relapse in participants after a first demyelinating event (33), while lower serum TG level and BMI could ameliorate central inflammation and reduce the accumulation of disability in relapsing-remitting MS patients (21). This evidence concerns the gene IL6 and relapsing-remitting multiple sclerosis.